Patents by Inventor Andrew S. Tasker
Andrew S. Tasker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240132506Abstract: Inhibitors of CDK9 that are pyrazolo[1,5-a]pyrimidine derivatives and salts thereof, corresponding to formula (I):Type: ApplicationFiled: November 3, 2023Publication date: April 25, 2024Applicant: Kronos Bio, Inc.Inventors: Peter MIKOCHIK, Joseph VACCA, David FREEMAN, Andrew S. TASKER
-
Patent number: 11845754Abstract: Inhibitors of CDK9 that are pyrazolo[1,5-a]pyrimidine derivatives and salts thereof, corresponding to formula (I):Type: GrantFiled: September 15, 2021Date of Patent: December 19, 2023Assignee: Kronos Bio, Inc.Inventors: Peter Mikochik, Joseph Vacca, David Freeman, Andrew S. Tasker
-
Publication number: 20220177488Abstract: The present invention relates to compounds and compositions capable of acting as inhibitors of small ubiquitin-like modifier (SUMO) family of proteins. The compounds and compositions may be used in the treatment of cancer. There are disclosed, inter alia, methods of inhibiting an E1 enzyme, and compounds useful for inhibiting an E1 enzyme.Type: ApplicationFiled: March 19, 2020Publication date: June 9, 2022Inventors: Xiaohu Ouyang, Miles Kubota, Ted Charles Judd, Andrew S. Tasker
-
Publication number: 20220002305Abstract: Inhibitors of CDK9 that are pyrazolo[1,5-a]pyrimidine derivatives and salts thereof, corresponding to formula (I):Type: ApplicationFiled: September 15, 2021Publication date: January 6, 2022Applicant: Kronos Bio, Inc.Inventors: Peter MIKOCHIK, Joseph VACCA, David FREEMAN, Andrew S. TASKER
-
Patent number: 11155560Abstract: Inhibitors of CDK9 that are pyrazolo[1,5-a]pyrimidine derivatives and salts thereof, corresponding to formula (I):Type: GrantFiled: October 29, 2019Date of Patent: October 26, 2021Assignee: kronos bio, inc.Inventors: Peter Mikochik, Joseph Vacca, David Freeman, Andrew S. Tasker
-
Publication number: 20200131189Abstract: Inhibitors of CDK9 that are pyrazolo[1,5-a]pyrimidine derivatives and salts thereof, corresponding to formula (I):Type: ApplicationFiled: October 29, 2019Publication date: April 30, 2020Inventors: Peter MIKOCHIK, Joseph VACCA, David FREEMAN, Andrew S. TASKER
-
Patent number: 8084479Abstract: The invention relates to methods of using thiazole compounds of Formula I and Formula II and compositions thereof for treating diseases mediated by protein kinase B (PKB) such as cancer and other proliferative disorders where the variables have the definitions provided herein.Type: GrantFiled: February 11, 2009Date of Patent: December 27, 2011Assignee: Amgen Inc.Inventors: Qingping Zeng, John G. Allen, Matthew P. Bourbeau, Celia Dominguez, Christopher H. Fotsch, Nianhe Han, Fang-Tsao Hong, Xin Huang, Matthew R. Lee, Aiwen Li, Qingyian Liu, James T. Rider, Seifu Tadesse, Andrew S. Tasker, Vellarkad N. Viswanadhan, Xianghong Wang, Kurt E. Weiler, George E. Wohlhieter, Guomin Yao, Chester Chenguang Yuan
-
Publication number: 20090270445Abstract: The invention relates to methods of using thiazole compounds of Formula I and Formula II and compositions thereof for treating diseases mediated by protein kinase B (PKB) such as cancer and other proliferative disorders where the variables have the definitions provided herein.Type: ApplicationFiled: February 11, 2009Publication date: October 29, 2009Applicant: Amgen Inc.Inventors: Qingping Zeng, John G. Allen, Matthew P. Bourbeau, Celia Dominguez, Christopher H. Fotsch, Nianhe Han, Fang-Tsao Hong, Xin Huang, Matthew R. Lee, Aiwen Li, Qingyian Liu, James T. Rider, Seifu Tadesse, Andrew S. Tasker, Vellarkad N. Viswanadhan, Xianghong Wang, Kurt E. Weiler, George E. Wohlhieter, Guomin Yao, Chester Chenguang Yuan
-
Patent number: 7514566Abstract: The invention relates to thiazole compounds of Formula I and Formula II and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such thiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.Type: GrantFiled: January 11, 2007Date of Patent: April 7, 2009Assignee: Amgen, Inc.Inventors: Qingping Zeng, John G. Allen, Matthew P. Bourbeau, Celia Dominguez, Christopher H. Fotsch, Nianhe Han, Fang-Tsao Hong, Xin Huang, Matthew R. Lee, Aiwen Li, Qingyian Liu, James T. Rider, Seifu Tadesse, Andrew S. Tasker, Vellarkad N. Viswanadhan, Xianghong Wang, Kurt E. Weiler, George E. Wohlhieter, Guomin Yao, Chester Chenguang Yuan
-
Patent number: 7365093Abstract: A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.Type: GrantFiled: February 23, 2005Date of Patent: April 29, 2008Assignee: Abbott LaboratoriesInventors: Martin Winn, Steven A. Boyd, Charles W. Hutchins, Hwan-Soo Jae, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Bryan K. Sorensen, Bruce G. Szczepankiewicz, Kenneth J. Henry, Gang Liu, Steven J. Wittenberger, Steven A. King
-
Patent number: 7208517Abstract: A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, a method of antagonizing endothelin, methods for the inhibition of bone metastases, methods for the prevention of growth of new metastases, methods for the inhibition of bone turnover, and methods for the prevention of bone loss in patients, including cancer patients, using an endothelin ET-A receptor antagonist.Type: GrantFiled: August 31, 2000Date of Patent: April 24, 2007Assignee: Abbott LabortoriesInventors: Martin Winn, Steven A. Boyd, Charles W. Hutchins, Hwan-Soo Jae, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Bryan K. Sorensen, Bruce G. Szczepankiewicz, Kenneth J. Henry, Gang Liu, Steven J. Wittenberger, Steven A. King, Todd J. Janus, Robert J. Padley
-
Patent number: 6946481Abstract: A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.Type: GrantFiled: October 8, 2002Date of Patent: September 20, 2005Assignee: Abbott LaboratoriesInventors: Martin Winn, Steven A. Boyd, Charles W. Hutchins, Hwan-Soo Jae, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Bryan K. Sorensen, Bruce G. Szczepankiewicz, Kenneth J. Henry, Gang Liu, Steven J. Wittenberger, Steven A. King
-
Patent number: 6514964Abstract: The invention comprises novel compounds that are effective in the prophylaxis and treatment of diseases, such as integrin receptors mediated diseases, in particular, diseases or conditions mediated by integrin receptors, such as &agr;v&bgr;3, &agr;v&bgr;5, &agr;v&bgr;6 and the like. The invention encompasses novel compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of such diseases and disorders. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.Type: GrantFiled: September 26, 2000Date of Patent: February 4, 2003Assignee: Amgen Inc.Inventors: Zhidong Chen, Celia Dominguez, Ellen Grenzer-Laber, Nianhe Han, Longbing Liu, Ofir A. Moreno, Melvin C. Rutledge, Andrew S. Tasker
-
Patent number: 6462194Abstract: A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.Type: GrantFiled: May 15, 2000Date of Patent: October 8, 2002Assignee: Abbott LaboratoriesInventors: Martin Winn, Steven A. Boyd, Charles W. Hutchins, Hwan-Soo Jae, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Bryan K. Sorensen, Bruce G. Szczepankiewicz, Kenneth J. Henry, Gang Liu, Steven J. Wittenberger, Steven A. King
-
Patent number: 6380241Abstract: A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.Type: GrantFiled: November 17, 2000Date of Patent: April 30, 2002Assignee: Abbott LaboratoriesInventors: Martin Winn, Steven A. Boyd, Charles W. Hutchins, Hwan-Soo Jae, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Bryan K. Sorensen, Bruce G. Szczepankiewicz, Kenneth J. Henry, Gang Liu, Steven J. Wittenberger, Steven A. King
-
Patent number: 6310095Abstract: Compounds having the formula or a pharmaceutically acceptable salt thereof wherein R1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L2—, and (i) heterocyclic-L2—; R2 is selected from (a) (b) —C(O)NH—CH(R14)—C(O)OR15, (d) —C(O)NH—CH(R14)—C(O)NHSO2R16, (e) —C(O)NH—CH(R14)-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R14)—C(O)NR17R18; R3 is substituted or unsubstituted heterocyclic or aryl, substituted or unsubstituted cycloalkyl or cycloalkenyl, and —P(W)RR3RR3′; R4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L1 is absent or is selected from (a) —L4—N(R5)—L5—, (b) —L4—O—L5—, (c) —L4—S(O)n—L5— (d) —L4—L6—C(W)—N(R5)—L5&Type: GrantFiled: May 7, 1998Date of Patent: October 30, 2001Assignee: University of PittsburghInventors: Said M. Sebti, Andrew D. Hamilton, David J. Augeri, Kenneth J. Barr, Stephen A. Fakhoury, David A. Janowick, Douglas M. Kalvin, Stephen J. O'Connor, Saul H. Rosenberg, Wang Shen, Rolf E. Swenson, Bryan K. Sorenson, Gerard M. Sullivan, Andrew S. Tasker, James T. Wasicak, Lissa T. J. Nelson, Kenneth J. Henry, Le Wang
-
Patent number: 6204293Abstract: Compounds having the formula or a pharmaceutically acceptable salt thereof wherein R1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L2—, and (i) heterocyclic-L2—; R2 is selected from (b) —C(O)NH—CH(R14)—C(O)OR15, (d) —C(O)NH—CH(R14)—C(O)NHSO2R16, (e) —C(O)NH—CH(R14)-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R14)—C(O)NR17R18; R3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L1 is absent or is selected from (a) —L4—N(R5)—L5—, (b) —L4—O—L5—, (c) —L4—S(O)n—L5— (d) —L4—L6—C(W)—N(R5)—L5—, (e) —L4—L6—S(O)m—N(R5)—L5 —, (f) —L4—N(R5)&mType: GrantFiled: May 7, 1998Date of Patent: March 20, 2001Assignee: University of PittsburghInventors: Said M. Sebti, Andrew D. Hamilton, David J. Augeri, Kenneth J. Barr, Stephen A. Fakhoury, David A. Janowick, Douglas M. Kalvin, Stephen J. O'Connor, Saul H. Rosenberg, Wang Shen, Rolf E. Swenson, Bryan K. Sorensen, Gerard M. Sullivan, Andrew S. Tasker, James T. Wasicak, Lissa T. J. Nelson, Kenneth J. Henry, Le Wang, Gang Liu, Indrani W. Gunawardana
-
Patent number: 6162927Abstract: A compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.Type: GrantFiled: August 4, 1997Date of Patent: December 19, 2000Assignee: Abbott LaboratoriesInventors: Martin Winn, Steven A. Boyd, Charles W. Hutchins, Hwan-Soo Jae, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Bryan K. Sorensen, Bruce G. Szczepankiewicz, Kenneth J. Henry, Gang Liu, Steven J. Wittenberger, Steven A. King
-
Patent number: 6124341Abstract: A compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.Type: GrantFiled: May 29, 1998Date of Patent: September 26, 2000Assignee: Abbott LaboratoriesInventors: Andrew S. Tasker, Martin Winn, Steven A. Boyd, Hwan-Soo Jae, Thomas W. von Geldern, Bryan K. Sorensen, Kenneth J. Henry
-
Patent number: 5767144Abstract: A compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.Type: GrantFiled: May 30, 1995Date of Patent: June 16, 1998Assignee: Abbott LaboratoriesInventors: Martin Winn, Steven A. Boyd, Charles W. Hutchins, Hwan-Soo Jae, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Bryan K. Sorensen